Skip to content

Dexmedetomidine for selective nerve root injection in the treatment of lumbar disc herniation with radiculopathy

Dexmedetomidine for selective nerve root injection in the treatment of lumbar disc herniation with radiculopathy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032881
Enrollment
Unknown
Registered
2020-05-14
Start date
2020-05-18
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disc herniation with radiculopathy

Interventions

Local anesthetics + diprosone:Nerve root block
Local anesthetic + dexmedetomidine:Nerve root block

Sponsors

Chengdu Fifth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The pain physician records the VAS score and modq score of pain after inquiring the history and physical examination. MRI results should be consistent with clinical symptoms, and diagnostic nerve root block should be performed. Patients receive 1 ml of 2% lidocaine under the guidance of ultrasound. If there is a positive reaction in selective nerve root block, they are included in the study group. 2. Patients over 18 years old; 3. All patients with LDH recorded in MRI showed unilateral radiculopathy, which was consistent with clinical symptoms; 4. Patients with VAS score = 5; 5. The patients whose symptoms lasted less than 3 months did not receive enough conservative treatment (3 weeks); 6. Obtain informed written consent.

Exclusion criteria

Exclusion criteria: 1. Patients with cauda equina syndrome; 2. Patients with motor nerve dysfunction of large muscle; 3. Patients with chronic radiculopathy > 3 months; 4. Patients with multilevel disc prolapse (> grade 2), contralateral radiculopathy and bilateral radiculopathy; 5. Patients with recurrent disc prolapse, major axial pain and high lumbar disc prolapse (above L3-4); 6. Patients with spondylolisthesis and trauma; 7. Patients with radiculopathy caused by infection; 8. Patients who refused to accept the study; 9. Patients with local skin infection.

Design outcomes

Primary

MeasureTime frame
VASscore;ODIscore;

Secondary

MeasureTime frame
Occurrence of bradycardia after treatment;Incidence of hypotension after treatment;

Countries

China

Contacts

Public ContactRao Xinyi

Chengdu Fifth People's Hospital

250182223@qq.com+86 13880840183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026